KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV.

Márton Kolossváry, Irini Sereti, Markella V Zanni, Carl J Fichtenbaum, Judith A Aberg, Gerald S Bloomfield, Carlos D Malvestutto, Judith S Currier, Sarah M Chu, Marissa R Diggs, Alex B Lu, Christopher deFilippi, Borek Foldyna, Sara McCallum, Craig A Sponseller, Michael T Lu, Pamela S Douglas, Heather J Ribaudo, Steven K Grinspoon

J Clin Invest 135(22) e196021

PMID40924496
PMCIDPMC12618077
DOI10.1172/JCI196021
发表日期2025-09-09
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:ROC 图;Figure 3:ROC 图;Figure 4:AI 判定为 other。
摘要

摘要

BACKGROUNDStatin therapy lowers the risk of major adverse cardiovascular events (MACE) among people with HIV (PWH). Residual risk pathways contributing to excess MACE beyond LDL-cholesterol (LDL-C) are not well understood. Our objective was to evaluate the association of statin-responsive and other inflammatory and metabolic pathways with MACE in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).METHODSCox proportional hazards models were used to assess the relationship between MACE and proteomics measurements at study entry and year 2, adjusting for time-updated statin use and the baseline 10-year atherosclerotic cardiovascular disease risk score. We built a machine-learning (ML) model to predict MACE using baseline protein values with significant associations.RESULTSFor 765 individuals (age: 50.8 ± 5.9 years, 82% men, 18% women), among 7 proteins changing with statin versus placebo, angiopoietin-related protein 3 (ANGPTL3) related most strongly to MACE (adjusted HR [aHR]: 2.31 per 2-fold-higher levels; 95% CI: 1.11-4.80; P = 0.03), such that lower levels of ANGPTL3 achieved with statin therapy were associated with lower MACE risk. Among 248 proteins that did not change in response to statin therapy, 26 were associated with MACE at a FDR below 0.05. These proteins represented a predominantly humoral immune response, leukocyte chemotaxis, and cytokine pathways. Our proteomics ML model achieved a 10-fold cross-validated concordance index (C-index) of 0.74 ± 0.11 to predict MACE, improving on models using traditional risk prediction scores only (C-index: 0.61 ± 0.18).CONCLUSIONSANGPTL3, as well as key inflammatory pathways, may contribute to a residual risk of MACE among PWH, beyond LDL-C.TRIAL REGISTRATIONClinicalTrials.gov: NCT02344290.FUNDINGNIH, Kowa Pharmaceuticals America, Gilead Sciences, ViiV Healthcare.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. CONSORT diagram of individuals included in the current analysis. Overall, 765 individuals were included in our analyses to evaluate the association between proteomics markers and MACE. QA, quality assurance; QC, quality control.
非 KM Figure
Figure 2Figure 2. Association between proteomics markers and MACE or hard MACE. ( A ) Volcano plot of HRs and P values for given proteins and MACE. HRs were estimated from Cox proportional hazards models using both potential proteomics measurements including statin use as a time-dependent covariate and 10-year baseline ASCVD risk score. HRs are per protein doubling. Red proteins indicate associations at an FDR below 0.05 level. The x axis is on a log 2 scale. Dotted line indicates a nominal P value of 0.05. Dashed line indicates a HR of 1. ( B ) Volcano plot of HRs and P values for given proteins and hard MACE. Hard MACE is defined as cardiovascular death, myocardial infarction, or stroke. HRs were estimated from Cox proportional hazards models using both potential proteomics measurements including statin use as a time-dependent covariate and baseline 10-year ASCVD risk score. HRs are per protein doubling. Red proteins indicate associations at an FDR below 0.05. The x axis is on a log 2 scale. Dotted line indicates a nominal P value of 0.05. Dashed line indicates a HR of 1. ANGPT2, angiopoietin-2; CD70, CD70 antigen; CD83, CD83 antigen; CSF1, processed macrophage colony-stimulating factor 1; CXCL13, C-X-C motif chemokine 13; FABP4, fatty acid–binding protein, adipocyte; GAL9, galectin-9; GRN, paragranulin; HGF, hepatocyte growth factor α chain; MCP2, C-C motif chemokine 8; MCP3, C-C motif chemokine 7; NOS3, nitric oxide synthase, endothelial; NT-PROBNP, NT-proBNP; OPN, osteopontin; PDCD1, programmed cell death protein 1; SHPS1, tyrosine-protein phosphatase non-receptor-type substrate 1; TCN2, transcobalamin-2; TNFRSF9, TNF receptor superfamily member 9; TNFSF13B, TNF ligand superfamily member 13b, membrane form; VEGFA, vascular endothelial growth factor A.
非 KM Figure
Figure 3Figure 3. Protein-protein interaction and enrichment analysis among proteins showing a significant association with MACE or hard MACE. ( A ) Confidence-based protein interaction network using all available interactions sources. The width of the edges between the proteins represents the overall confidence score. The average number of connections between the protein nodes is 6.21, while IL-6 and IL-8 are connected to 21 and 18 proteins, respectively. ( B ) Gene Ontology and Reactome functional enrichments analysis. Gene Ontology biological processes, molecular function, and Reactome pathway enrichment all indicated increased representation of cytokine and chemokine processes and pathway functions within our significant proteins. CCR, chemokine-chemokine receptor.
非 KM Figure
Figure 4Figure 4. Cross-validated performance of significant proteins, unchanged with statin therapy, to predict MACE. ( A ) Stratified 10-fold cross-validated, time-dependent C-index of Cox elastic net machine learning models. Model 1: statin randomization + 10-year ASCVD risk score; model 2: baseline values of proteins associated with MACE; model 3: model 1 + model 2. ( B ) Importance of the features with a HR different from at least 1 in one of the models. Bars represent standardized average standardized HRs from the 10-fold cross-validation. CV, cross-validation.
非 KM Figure